Quadrivalent inactivated influenza vaccine (VaxigripTetra™)-Reference-Cited by-同舟云学术

Quadrivalent inactivated influenza vaccine (VaxigripTetra™)

Published:2017-11-27 Issue:1 Volume:17 Page:1-11
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Gresset-Bourgeois Viviane¹,Leventhal Phillip S.²,Pepin Stéphanie³,Hollingsworth Rosalind⁴,Kazek-Duret Marie-Pierre⁵,De Bruijn Iris³,Samson Sandrine I.¹

Affiliation:

1. Global Medical Affairs, Sanofi Pasteur, Lyon, France

2. 4Clinics, Paris, France

3. Clinical Development, Sanofi Pasteur, Marcy l’Étoile, France

4. Global Medical Affairs, Sanofi Pasteur, Swiftwater, USA

5. R&D, Sanofi Pasteur, Marcy l’Étoile, France

Funder

Sanofi Pasteur

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2018.1407650

Reference62 articles.

1. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study

2. The evolving history of influenza viruses and influenza vaccines

3. Impact of Influenza B Lineage-Level Mismatch Between Trivalent Seasonal Influenza Vaccines and Circulating Viruses, 1999–2012

4. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and safety evaluation of a newly manufactured recombinant Baculovirus-Expressed quadrivalent influenza vaccine in adults 18 years old and Above: An Open-Label, phase III extension study;International Immunopharmacology;2024-07

2. The Screening and Mechanism of Influenza-Virus Sensitive MDCK Cell Lines for Influenza Vaccine Production;Diseases;2024-01-10

3. Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults;Vaccine;2023-07

4. Highly Pathogenic Avian Influenza Vaccines: challenges for innovation, technological development and pandemic preparedness;2023-06-04

5. Post-Marketing Safety Surveillance of Quadrivalent Influenza Vaccine (VaxigripTetra) in Children Aged 6 to 35 Months in South Korea;Infectious Diseases and Therapy;2023-06